Luc Therapeutics, Inc. (“Luc Therapeutics”), founded in 2010, is a private biotechnology company based in Cambridge, MA and funded by Atlas Venture Inc., Clal Biotechnology Industries (CBI) and Slater Technology Fund. The company is translating new understandings of human neurobiology into differentiated medicines for serious psychiatric and neurological diseases.
In March 2017 Luc Therapeutics merged with Saniona’s Boston based spinout Ataxion Inc.
In addition to ownership in the merged Luc Therapeutics, Saniona is also eligible to receive royalties on any potential products developed and commercialized from the Ataxia-program.
Saniona is responsible for key program discovery activities, which are conducted under a research and development agreement between Luc Therapeutics and Saniona on fee for service basis.